

Clinical imaging core lab

Advance your clinical trial with a global neuroimaging core lab

Partnering with experts in brain imaging analysis



Neurophet's Approach to Imaging Core Lab Services



Study Design

Provides comprehensive scientific and medical assistance in the study design phase.



Study Start Up

Delivers study-specific technical documents, conducts site training, and performs site qualification.



Image Management

Fully integrated with data management systems for image submission, quality control and query resolution.



Neuro-image Analysis

Executes precise image processing and analysis with cutting edge technologies that align with established protocols, covering all aspects of enrollment, efficacy, and safety.



Data Analysis

comprehensive biostatistical services that enhance and support data-driven clinical decision-making.

Area of Clinical Research

Area to Clinical Research	Modality	Target Biomarker	Neurophet's Solutions	Outcomes & Benefits
Neuro- degenerative	MRI	Structural atrophy (T1)	Neurophet AQUA	126 ROIs volumetric analysis and atrophy measurement based on normative database, WMH quantification based on Fazekas scale assessment.
		White Matter Hyperintensity (T2-FLAIR)		
		ARIA-E (Edema, Effusion)	Neurophet AQUA AD	ARIA-E, ARIA-H severity and longitudinal tracking, Brain volume tracking after amyloid target therapy, Amyloid positivity prediction.
		ARIA-H (Hemorrhage)		
	PET	Amyloid	Neurophet SCALE PET	Enhanced PET tracer /SUVR measurements and Centiloid Scale for effective drug development.
		Tau		
		FDG		
CNS Demyelinating (MS, NMOSD, MOGAD)	MRI	T2-FLAIR	Neurophet AQUA	Track and visualize lesion changes to assess disease progression and drug efficacy. Use only FLAIR sequence for brain structure volume calculations, enhancing analysis.
Cerebrovascular	MRI	Cerebral Microbleeds	Neurophet SCALE MRI	Accurate cerebral microbleed detection for comprehensive vascular assessment.
Developmental	MRI	T1/T2 Infant Volumetry	Neurophet AQUA Pediatrics	Brain image analysis and volume measurements for 0-24 months old (including preterm baby).

About Neurophet

Partner with Neurophet to leverage Al-driven neuroimaging expertise for breakthroughs in pharma and biotech research

30+

Neuroimaging experts 6

In-house Medical Doctors 20+

Global

100+

Hospital use

Global Phase 3

Extensive experience in conducting clinical trials

AI-Powered analysis

Analyze large datasets of neuro-imaging with speed and precision, facilitating effective patient pre-identification.



Accurate and reliable

Experience trustworthy neuroimaging analysis with automated quantitative results that are accurate and reliable.

Customized service

Neurophet provides dedicated team for each study that is tailored to the individual needs.

Maximize efficiency

Streamlined work flows, time and cost savings, and accurate analysis of research outcomes with Neurophet empowers clinical decisions and optimal results.

Related Products



FDA 510(k) Cleared

Explore Neurodegenerative Disease & Multiple Sclerosis



Brain volume & lesion quantifying and tracking

SCALE PET

FDA 510(k) Cleared

See Alzhelmer's Disease (AD) with Centiloid




Amyloid, FDG, DAT, Tau PET Quantification

AQUA AD

Research only

Explore imaging biomarkers for AD DMT*



AD Imaging biomarker Quantification ARIA Detection & Severity grading

AQUA Pediatrics

Research only

Experience the changes in volumes within growing brains



Analysis for developmental brain

* Downse Modifying Therapy

